David W. Loring

David W. Loring

Auto-generated profile, based on publicly available information

David W. Loring

Department of Neurology, Emory University School of Medicine, Atlanta, USA

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in The Lancet Neurology
Verified
Journal Article
Closed access
KMKimford J Meador
Kimford J Meador
GBGus A Baker
Gus A Baker
NBNancy Browning
Nancy Browning
MCMorris J Cohen
Morris J Cohen
RBRebecca L Bromley
Rebecca L Bromley
DLDavid W Loring
David W Loring

8 December 2014 in Epilepsia
Verified
Journal Article
Open access
PDF file
DDDaniel L. Drane
Daniel L. Drane
DLDavid W. Loring
David W. Loring
NVNatalie L. Voets
Natalie L. Voets
MPMichele Price
Michele Price
JOJeffrey G. Ojemann
Jeffrey G. Ojemann
RGRobert E. Gross
Robert E. Gross
Summary: Objectives: Patients with temporal lobe epilepsy (TLE) experience significant deficits in category‐related object recognition and naming following standard surgical approaches. These deficits may result from a decoupling of core processing modules (e.g., language, visual processing, and semantic memory), due to “collateral damage” to temporal regions outside the hippocampus following open surgical approaches. We predicted that stereotactic laser amygdalohippocampotomy (SLAH) would minimize such deficits because it preserves white matter pathways and neocortical regions that are critical for these cognitive processes.Methods: Tests of naming and recognition of common nouns (Boston Naming Test) and famous persons were compared with nonparametric analyses using exact tests between a group of 19 patients with medically intractable mesialTLEundergoingSLAH(10 dominant, 9 nondominant), and a comparable series ofTLEpatients undergoing standard surgical approaches (n = 39) using a prospective, nonrandomized, nonblinded, parallel‐group design.Results: Performance declines were significantly greater for the patients with dominantTLEwho were undergoing open resection versusSLAHfor naming famous faces and common nouns (F = 24.3, p < 0.0001, η2 = 0.57, and F = 11.2, p < 0.001, η2 = 0.39, respectively), and for the patients with nondominantTLEundergoing open resection versusSLAHfor recognizing famous faces (F = 3.9, p < 0.02,η2 = 0.19). When examined on an individual subject basis, noSLAHpatients experienced any performance declines on these measures. In contrast, 32 of the 39 patients undergoing standard surgical approaches declined on one or more measures for both object types (p < 0.001, Fisher's exact test). Twenty‐one of 22 left (dominant)TLEpatients declined on one or both naming tasks after open resection, while 11 of 17 right (nondominant)TLEpatients declined on face recognition.Significance: Preliminary results suggest (1) naming and recognition functions can be spared inTLEpatients undergoingSLAH, and (2) the hippocampus does not appear to be an essential component of neural networks underlying name retrieval or recognition of common objects or famous faces.

27 January 2015 in Neurology
Verified
Journal Article
Closed access
PDF file
GBGus A. Baker
Gus A. Baker
RBRebecca L. Bromley
Rebecca L. Bromley
MBMaria Briggs
Maria Briggs
CCChristopher P. Cheyne
Christopher P. Cheyne
MCMorris J. Cohen
Morris J. Cohen
LKLoretta Kerr
Loretta Kerr
Objective: To delineate the risk to child IQ associated with frequently prescribed antiepileptic drugs. Methods: Children born to women with epilepsy (n = 243) and women without epilepsy (n = 287) were recruited during pregnancy and followed prospectively. Of these, 408 were blindly assessed at 6 years of age. Maternal and child demographics were collected and entered into statistical models. Results: The adjusted mean IQ was 9.7 points lower (95% confidence interval [CI] −4.9 to −14.6; p < 0.001) for children exposed to high-dose (>800 mg daily) valproate, with a similar significant effect observed for the verbal, nonverbal, and spatial subscales. Children exposed to high-dose valproate had an 8-fold increased need of educational intervention relative to control children (adjusted relative risk, 95% CI 8.0, 2.5–19.7; p < 0.001). Valproate at doses <800 mg daily was not associated with reduced IQ, but was associated with impaired verbal abilities (−5.6, 95% CI −11.1 to −0.1; p = 0.04) and a 6-fold increase in educational intervention (95% CI 1.4–18.0; p = 0.01). In utero exposure to carbamazepine or lamotrigine did not have a significant effect on IQ, but carbamazepine was associated with reduced verbal abilities (−4.2, 95% CI −0.6 to −7.8; p = 0.02) and increased frequency of IQ <85. Conclusions: Consistent with data from younger cohorts, school-aged children exposed to valproate at maternal doses more than 800 mg daily continue to experience significantly poorer cognitive development than control children or children exposed to lamotrigine and carbamazepine.

1 December 2004 in Epilepsy & Behavior
Verified
Journal Article
Closed access
DLDavid W. Loring
David W. Loring
KMKimford J. Meador
Kimford J. Meador
GLGregory P. Lee
Gregory P. Lee

1 August 2014 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
KMKimford J. Meador
Kimford J. Meador
GBGus A. Baker
Gus A. Baker
NBNancy Browning
Nancy Browning
MCMorris J. Cohen
Morris J. Cohen
RBRebecca L. Bromley
Rebecca L. Bromley
DLDavid W. Loring
David W. Loring
Similar to alcohol, some antiepileptic drugs (AEDs) can cause widespread neuronal apoptosis in the immature animal brain.1-8 This effect is dose dependent, occurs at therapeutically relevant blood levels, and requires only brief exposure. The associated behavioral deficits in animals may be due more to dysfunction in the surviving neurons than to the loss of neurons.9 Consistent with these findings in animals, some AEDs have been associated with reduced cognitive abilities in children exposed in utero.10-14 Susceptibility of the immature brain to AED-induced apoptosis likely extends beyond birth, so concern has been raised that breastfeeding during maternal AED therapy might be harmful to the child. In contrast, known positive effects of breastfeeding exist for the child and mother.15 Therefore, a clinical dilemma presents as to the relative benefits and risks of breastfeeding during AED therapy. No animal data to date directly address this issue. In an ongoing prospective investigation of neurodevelopmental effects of AEDs on cognitive outcomes in children of mothers with epilepsy, the preliminary results at age 3 years found no difference in IQ for children who breastfed vs those who did not.16 However, IQ at age 6 years is more predictive of school performance and adult abilities.17 Furthermore, additional cognitive domains can be assessed at age 6 years vs at age 3 years. So, we examined cognitive outcomes in our cohort at age 6 years.

18 October 2007 in Neuropsychology Review
Verified
Journal Article
Closed access
PDF file
DLDavid W. Loring
David W. Loring
SMSusan Marino
Susan Marino
KMKimford J. Meador
Kimford J. Meador